Seeking Alpha

Coronado Biosciences' CNDO-201 misses endpoints in Crohn's disease trial

  • Coronado Biosciences' (CNDO) TSO did not meet its primary endpoint in a Phase 2 Crohn's disease trial.
  • TRUST-1's primary endpoint was a 100-point decrease in CDAI and its secondary endpoint was remission (CDAI <150 points). Neither endpoint was met in patients with moderate-to-severe Crohn's disease.
  • The company says "the lack of overall response was driven by higher-than-expected placebo response rate in patients with CDAI < 290" and although CEO Harlan Weisman is "disappointed with the topline results," he says the company is "encouraged to see TSO's effect in patients with CDAI > 290."
  • Results from a second interim analysis of a second Phase 2 study are expected in Q4. (PR)
  • The shares fell 13% Friday.
  • Update 9:02: Coming off a halt, CNDO is down 68%.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|